Daniel Bagi Email & Phone Number

Delivering key opinion leader research, technology, and consulting solutions to the biopharmaceutical industry throughout Latin America.

I provide in-licensing, sales and marketing for medical devices.

Development of pharmaceutical products for Latin America and the Middle East. Instrumental in securing some exclusive agency agreements with Canadian, European and US companies for the Middle East and Mexico.

Senior consultant to U.S. breast cancer diagnostic company. Managed a series of outside consultants covering the clinical & regulatory affairs of the company. Through my contacts, EM Diagnostics built a world-class Medical Scientific Advisory Board, helping guide the company clear major clinical and regulatory hurdles.

President & CEO of consulting company serving the biotechnology industry in North America, providing regulatory, licensing and market information. Clients included US, Canadian, and Mexican pharmaceutical companies. Secured several licensing deals between US and Mexican pharmaceutical companies.

Worked as an external biotechnology consultant/analyst for a New York-based investment bank, advising on investment decisions in biotechnology sector and was instrumental in raising capital for several start-up biotech companies. Also wrote research reports on the biotech sector, with an emphasis on cancer and biopharmaceutical companies.

Directed the clinical and pre-clinical programs in oncology, organized scientific and medical advisory boards. Led the planning for the Phase I clinical trial of a semi-synthetic newly-patented vinca alkaloid. Coordinated the contracting of the CRO (Contract Research Organization) for the monitoring of the US Phase I study. Oversaw the patenting strategy for the oncology portfolio. Active in presentations to the financial community and regulatory agencies

Directed the global Clinical Development of anti-cancer drugs and supervised the Medical Affairs function. Member of the Management Committee and a key participant in new business development, financing activities and strategic planning. Led the Phase II planning of the lead immunotherapeutic compound for pancreatic cancer in Canada and the US. Organized and participated in the Investigators’ meetings.Led the Phase II planning of lead immunotherapeutic compound for additional indications in cancer – advanced malignant melanoma, colon, stomach, renal and cervical. Presented the Company’s clinical program to financial institutions, regulatory agencies in Canada, the US and Mexico. Obtained Mexican approval of an immunotherapeutic product for malignant melanoma.

Doctor Of Medicine

Bachelor Of Arts